1 |
Mancia G, de Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
DOI
ScienceOn
|
2 |
Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-53.
DOI
ScienceOn
|
3 |
Masumiya H, Shijuku T, Tanaka H, Shigenobu K. Inhibition of myocardial L- and T-type currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol 1998;349:351-7.
DOI
|
4 |
Ge W, Ren J. Combined L-/T-type calcium channel blockers: ready for prime time. Hypertension 2009;53:592-4.
DOI
ScienceOn
|
5 |
Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003;83:117-61.
DOI
|
6 |
Shin HS. T-type channels and absence epilepsy. Cell Calcium 2006; 40:191-6.
DOI
ScienceOn
|
7 |
Ono K, Iijima T. Pathophysiological significance of T-type channels: properties and functional roles of T-type channels in cardiac pacemaking. J Pharmacol Sci 2005;99:197-204.
DOI
ScienceOn
|
8 |
Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007;30:621-6.
DOI
ScienceOn
|
9 |
Kinoshita H, Kuwahara K, Takano M, et al. T-type channel blockade prevents sudden death in mice with heart failure. Circulation 2009;120:745-52.
|
10 |
Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv Drug Deliv Rev 2007;59:904-22.
DOI
ScienceOn
|
11 |
Masuda Y, Takeguchi M, Arakawa C, et al. Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Arch Int Pharmacodyn Ther 1990;304:247-64.
|
12 |
Tanaka H, Shigenobu K. Efonidipine hydrochloride: a dual blocker of L- and T-type Ca2+ channels. Cardiovasc Drug Rev 2002;20:81-92.
|
13 |
Tochikubo O, Ikeda A, Miyajima E, Ishii M. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension 1996;27:1318-24.
DOI
ScienceOn
|
14 |
Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol 1998;32:331-6.
DOI
ScienceOn
|
15 |
Nakabeppu H, Asada M, Oda T, Shinozaki Y, Yajima T. Plasma and urinary metabolites of efonidipine hydrochloride in man. Xenobiotica 1996;26:229-39.
DOI
ScienceOn
|
16 |
Hermida RC, Ayala DE, Chayan L, Mojon A, Fernandez JR. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 2009;26:61-79.
DOI
ScienceOn
|
17 |
Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003;107:1401-6.
DOI
ScienceOn
|
18 |
Ohtomo N, Kamo T, Watanabe M, Yoneyama K, Tanaka Y, Hayashi R. Power spectral densities of temporal variations of blood pressures. Jpn J Appi Phys 1996;35:5571-82.
DOI
|
19 |
Yamashita T, Masuda Y, Sakai T, Tanaka S, Kasuya Y. NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta. Jpn J Pharmacol 1991;57:337-48.
DOI
|
20 |
Nold G, Herholz C, Sturm M, Hopf R, Lemmer B. Ambulatory blood pressure profiles in essential hypertensives after treatment with a new once daily nifedipine formulation. J Hum Hypertens 1999;13:173-7.
DOI
ScienceOn
|
21 |
White WB, Saunders E, Noveck RJ, Ferdinand K. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. Am J Hypertens 2003;16:739-45.
DOI
ScienceOn
|
22 |
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-21.
DOI
ScienceOn
|
23 |
Oh IY, Seo MK, Lee HY, et al. Beneficial effect of efonidipine, an L- and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild-to-moderate essential hypertension. Korean Circ J 2010;40:514-9.
DOI
ScienceOn
|
24 |
Saito T, Fujii K, Takizawa T, et al. Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina. Arzneimittelforschung 1996;46:861-7.
|